Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Still, many patients say the oral diabetes pill, no needles approach is worth it
Understanding interactions and appropriate dosing becomes crucial
Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est
MARTIN GROCOCK I have seen Mandie 3 times now and I am very impressed
Given proposed opioid and sedative mechanisms, combining DSIP with CNS depressants, opioid medications, or benzodiazepines should be avoided without direct medical supervision
Irisin Exerts a Therapeutic Effect against Myocardial Infarction via Promoting Angiogenesis
